Mylan to sell two drugs to get clearance for Meda buy


Drug giant Mylan has agreed to sell rights and assets related to products for treating muscle spasms and epilepsy to satisfy the government’s concerns that its $7.2 billion purchase of rival Meda would be anticompetitive. Under the agreement with the Federal Trade Commission, Mylan will relinquish its US marketing rights